1. Home
  2. ALT vs UROY Comparison

ALT vs UROY Comparison

Compare ALT & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • UROY
  • Stock Information
  • Founded
  • ALT 1997
  • UROY 2017
  • Country
  • ALT United States
  • UROY Canada
  • Employees
  • ALT N/A
  • UROY N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • UROY
  • Sector
  • ALT Health Care
  • UROY
  • Exchange
  • ALT Nasdaq
  • UROY Nasdaq
  • Market Cap
  • ALT 292.0M
  • UROY 336.8M
  • IPO Year
  • ALT N/A
  • UROY N/A
  • Fundamental
  • Price
  • ALT $3.83
  • UROY $3.15
  • Analyst Decision
  • ALT Strong Buy
  • UROY Strong Buy
  • Analyst Count
  • ALT 6
  • UROY 2
  • Target Price
  • ALT $17.40
  • UROY $4.00
  • AVG Volume (30 Days)
  • ALT 3.0M
  • UROY 2.6M
  • Earning Date
  • ALT 08-12-2025
  • UROY 07-16-2025
  • Dividend Yield
  • ALT N/A
  • UROY N/A
  • EPS Growth
  • ALT N/A
  • UROY N/A
  • EPS
  • ALT N/A
  • UROY N/A
  • Revenue
  • ALT $20,000.00
  • UROY $11,285,840.00
  • Revenue This Year
  • ALT N/A
  • UROY $228.36
  • Revenue Next Year
  • ALT $761,880.20
  • UROY N/A
  • P/E Ratio
  • ALT N/A
  • UROY N/A
  • Revenue Growth
  • ALT N/A
  • UROY N/A
  • 52 Week Low
  • ALT $2.90
  • UROY $1.43
  • 52 Week High
  • ALT $11.16
  • UROY $3.30
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • UROY 65.88
  • Support Level
  • ALT $3.35
  • UROY $2.51
  • Resistance Level
  • ALT $3.66
  • UROY $2.87
  • Average True Range (ATR)
  • ALT 0.19
  • UROY 0.16
  • MACD
  • ALT 0.07
  • UROY 0.05
  • Stochastic Oscillator
  • ALT 86.18
  • UROY 82.05

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.

Share on Social Networks: